Emergent BioSolutions announced that TRU-016 has been granted orphan drug designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) patients. TRU-016 is currently being evaluated in multiple human Phase 1 clinical studies for the treatment of CLL and non-Hodgkin’s lymphoma.

TRU-016 is a humanized anti-CD37, mono-specific protein. 

For more information call (301) 795-1800 or visit www.emergentbiosolutions.com.